2025 Q4 -tulosraportti
Vain PDF
3 päivää sitten
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
907
Myynti
Määrä
15
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 16 | - | - | ||
| 88 | - | - | ||
| 18 | - | - | ||
| 61 | - | - |
Ylin
544VWAP
Alin
516VaihtoMäärä
11 20 867
VWAP
Ylin
544Alin
516VaihtoMäärä
11 20 867
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 22 244 | 22 244 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 22 244 | 22 244 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 6.2. | |
| 2025 Q3 -tulosraportti | 24.10.2025 | |
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 31.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sittenSo the report is here - a really good report in my opinion: - Revenue: Growth of almost 25% - Profit after tax: 65 mkr (Margin: 11,0%) - EBITDA margin: 23,8% Comments: - The growth stands out! - Suspect a "one-off write-down" of approx. 10 mkr, which makes the result even better - Assistive devices: Monster quarter!!! - Medical technology: Very good, except for Multi-Ply - Multi-Ply, sounds like it will take quite a long time to get the business up to speed, but also that they have a plan - Specialty pharmaceuticals: Low margin, will gradually improve after midsummer - They are working down the debt somewhat So an excellent delivery, now we just have to hope for more acquisitions!!
·3.2.The stock has been pressured down since the last report. I believe the new report will give the stock a boost upwards! What do you think?6 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetDecline0%Unchanged0%+10%83%+20%17%- ·24.10.2025The report is here!! - Stable and good - Revenue slightly better than my forecast - Margin a few tenths of a percent lower than my forecast - XGX Pharma is doing well, initially at least - also a good pipeline for 2026 - Now there are easier comparables for upcoming quarters (profit margin) - BR still strong, hoping for more acquisitions in 2026 - Feels very well-managed Is there anything negative.... - XGX looks like it will be excellent, but always a bit worried about Danish acquisitions - Multi-Ply seems to be struggling a bit - Uniumedic seems to be tweaking production a bit, which increases costs slightly short-term, but probably good in the long run Nah, this will be good, already looking forward to 2026·3.12.2025Press release with management change today. Don't think there's unrest in the ranks, but rather a natural shift. Medical aids have been doing great under Tove's leadership, hope they find a good replacement! New person in charge of Medical Technology, don't know who was before... Now risk that there won't be any acquisitions for a while... - The 3rd (and smallest) business area has just received a new acquisition, XGX - Still hope there will be some acquisition in Q1 or Q2...
·9.10.2025 · MuokattuDavid Jern has been Medcaps CEO since 2021. What a great guy to have on the board of a company you own! Jern was CEO of Stille between 2014-2018. During that relatively short time, he carried out a very successful turnaround of the company. If you watch this clip ( https://www.youtube.com/watch?v=2Bj4uddKiks ) you understand what kind of person you are dealing with here – a super sensible "no nonsense" guy. He will make sure that the board does not become a yes-owner club! Can't see him sitting around and stroking anyone's hair. Now maybe it's not necessary, with such a good main owner as Linc – but still, it feels safe to have such a member on the board!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
3 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenSo the report is here - a really good report in my opinion: - Revenue: Growth of almost 25% - Profit after tax: 65 mkr (Margin: 11,0%) - EBITDA margin: 23,8% Comments: - The growth stands out! - Suspect a "one-off write-down" of approx. 10 mkr, which makes the result even better - Assistive devices: Monster quarter!!! - Medical technology: Very good, except for Multi-Ply - Multi-Ply, sounds like it will take quite a long time to get the business up to speed, but also that they have a plan - Specialty pharmaceuticals: Low margin, will gradually improve after midsummer - They are working down the debt somewhat So an excellent delivery, now we just have to hope for more acquisitions!!
- ·3.2.The stock has been pressured down since the last report. I believe the new report will give the stock a boost upwards! What do you think?6 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetDecline0%Unchanged0%+10%83%+20%17%
- ·24.10.2025The report is here!! - Stable and good - Revenue slightly better than my forecast - Margin a few tenths of a percent lower than my forecast - XGX Pharma is doing well, initially at least - also a good pipeline for 2026 - Now there are easier comparables for upcoming quarters (profit margin) - BR still strong, hoping for more acquisitions in 2026 - Feels very well-managed Is there anything negative.... - XGX looks like it will be excellent, but always a bit worried about Danish acquisitions - Multi-Ply seems to be struggling a bit - Uniumedic seems to be tweaking production a bit, which increases costs slightly short-term, but probably good in the long run Nah, this will be good, already looking forward to 2026·3.12.2025Press release with management change today. Don't think there's unrest in the ranks, but rather a natural shift. Medical aids have been doing great under Tove's leadership, hope they find a good replacement! New person in charge of Medical Technology, don't know who was before... Now risk that there won't be any acquisitions for a while... - The 3rd (and smallest) business area has just received a new acquisition, XGX - Still hope there will be some acquisition in Q1 or Q2...
- ·9.10.2025 · MuokattuDavid Jern has been Medcaps CEO since 2021. What a great guy to have on the board of a company you own! Jern was CEO of Stille between 2014-2018. During that relatively short time, he carried out a very successful turnaround of the company. If you watch this clip ( https://www.youtube.com/watch?v=2Bj4uddKiks ) you understand what kind of person you are dealing with here – a super sensible "no nonsense" guy. He will make sure that the board does not become a yes-owner club! Can't see him sitting around and stroking anyone's hair. Now maybe it's not necessary, with such a good main owner as Linc – but still, it feels safe to have such a member on the board!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
907
Myynti
Määrä
15
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 16 | - | - | ||
| 88 | - | - | ||
| 18 | - | - | ||
| 61 | - | - |
Ylin
544VWAP
Alin
516VaihtoMäärä
11 20 867
VWAP
Ylin
544Alin
516VaihtoMäärä
11 20 867
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 22 244 | 22 244 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 22 244 | 22 244 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 6.2. | |
| 2025 Q3 -tulosraportti | 24.10.2025 | |
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 31.1.2025 |
2025 Q4 -tulosraportti
Vain PDF
3 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 6.2. | |
| 2025 Q3 -tulosraportti | 24.10.2025 | |
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 31.1.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenSo the report is here - a really good report in my opinion: - Revenue: Growth of almost 25% - Profit after tax: 65 mkr (Margin: 11,0%) - EBITDA margin: 23,8% Comments: - The growth stands out! - Suspect a "one-off write-down" of approx. 10 mkr, which makes the result even better - Assistive devices: Monster quarter!!! - Medical technology: Very good, except for Multi-Ply - Multi-Ply, sounds like it will take quite a long time to get the business up to speed, but also that they have a plan - Specialty pharmaceuticals: Low margin, will gradually improve after midsummer - They are working down the debt somewhat So an excellent delivery, now we just have to hope for more acquisitions!!
- ·3.2.The stock has been pressured down since the last report. I believe the new report will give the stock a boost upwards! What do you think?6 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetDecline0%Unchanged0%+10%83%+20%17%
- ·24.10.2025The report is here!! - Stable and good - Revenue slightly better than my forecast - Margin a few tenths of a percent lower than my forecast - XGX Pharma is doing well, initially at least - also a good pipeline for 2026 - Now there are easier comparables for upcoming quarters (profit margin) - BR still strong, hoping for more acquisitions in 2026 - Feels very well-managed Is there anything negative.... - XGX looks like it will be excellent, but always a bit worried about Danish acquisitions - Multi-Ply seems to be struggling a bit - Uniumedic seems to be tweaking production a bit, which increases costs slightly short-term, but probably good in the long run Nah, this will be good, already looking forward to 2026·3.12.2025Press release with management change today. Don't think there's unrest in the ranks, but rather a natural shift. Medical aids have been doing great under Tove's leadership, hope they find a good replacement! New person in charge of Medical Technology, don't know who was before... Now risk that there won't be any acquisitions for a while... - The 3rd (and smallest) business area has just received a new acquisition, XGX - Still hope there will be some acquisition in Q1 or Q2...
- ·9.10.2025 · MuokattuDavid Jern has been Medcaps CEO since 2021. What a great guy to have on the board of a company you own! Jern was CEO of Stille between 2014-2018. During that relatively short time, he carried out a very successful turnaround of the company. If you watch this clip ( https://www.youtube.com/watch?v=2Bj4uddKiks ) you understand what kind of person you are dealing with here – a super sensible "no nonsense" guy. He will make sure that the board does not become a yes-owner club! Can't see him sitting around and stroking anyone's hair. Now maybe it's not necessary, with such a good main owner as Linc – but still, it feels safe to have such a member on the board!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
907
Myynti
Määrä
15
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 16 | - | - | ||
| 88 | - | - | ||
| 18 | - | - | ||
| 61 | - | - |
Ylin
544VWAP
Alin
516VaihtoMäärä
11 20 867
VWAP
Ylin
544Alin
516VaihtoMäärä
11 20 867
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 22 244 | 22 244 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 22 244 | 22 244 | 0 | 0 |